A RESEARCH STUDY TO ASSESS THE ALPHA-INTERFERON EFFECTIVENESS AMONG MALES SUFFERING FROM HEPATITIS C (HCV) by Dr Saba Khalid, Dr Arshia Ahmad, Dr Nazish Tanveer, Dr. Shabeeh e Zahra
IAJPS 2019, 06 (05), 8815-8819                     Saba Khalid et al                         ISSN 2349-7750 
 
 
w w w . i a j p s . c o m  
 
Page 8815 
 
        CODEN [USA]: IAJPBB                        ISSN: 2349-7750 
 
  INDO AMERICAN JOURNAL OF 
 PHARMACEUTICAL SCIENCES 
                              
Available online at: http://www.iajps.com                                  Research Article 
A RESEARCH STUDY TO ASSESS THE ALPHA-INTERFERON 
EFFECTIVENESS AMONG MALES SUFFERING FROM 
HEPATITIS C (HCV) 
1Dr Saba Khalid, 2Dr Arshia Ahmad, 3Dr Nazish Tanveer, 4Dr. Shabeeh e Zahra 
1Nishtar Hospital Multan. 
Article Received: March 2019        Accepted: April 2019           Published: May 2019 
Abstract: 
Background: For the treatment of chronic hepatitis C, chemotherapy with different drugs is used a-interferon is one 
of these drugs. 
Objectives: The objective of this study was to determine the efficiency of a-interferon in males diagnosed with Hepatitis 
C.  
Patients and Methods: This research was completed in the timeframe of February to August 2018 at Jinnah Hospital, 
Lahore. Total patients were selected for study were 20 males diagnosed with Hepatitis C. The age bracket for these 
patients was between 24 – 51 years of age. The selected patients were provided with an injection of a-interferon three 
times a week. After execution of 6 months of chemotherapy, their sera were assessed. 
Results: The number of patients who became negative for HCV after six months of management with a-interferon was 
18 (90%). The levels of serum total bilirubin before and after management with a-interferon were (0.939 ± 0.07) mg/dl 
and (0.924 ± 0.09) mg/dl respectively which were normal. The outcomes noticed for serum direct and indirect bilirubin 
were identical. Before treatment, there observed elevated levels of serum Glutamate Pyruvate Transaminase (SGPT) 
(337.40 ± 75.38) U/I and after management with a-interferon, these levels became normal (26.8 ± 7.42) U/I before 
and after management with a-interferon, the levels of alkaline phosphatase (ALP) were normal in patients of our 
study. 
Conclusion: Virologic and biochemical reactions can be maintained by a-interferon therapy in patients of chronic 
hepatitis C. Similar to other nations of the world, it is very advantageous for management of SGPT values within a 
normal range in patients of Hepatitis C. 
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INTRODUCTION: 
Dietary compounds are maintained in a complicated 
structure called liver. Toxic compounds are excreted 
and metabolized by the liver. It is also involved in the 
composition of various metabolically significant 
compound [1]. Inflammation of liver occurs due to 
chronic Hepatitis C. It is followed by cirrhosis of liver, 
necrosis and fibrosis [2]. In patients of chronic 
hepatitis C and cirrhosis, there has been observed 
greater chances of liver cancer [3]. In hepatitis, the test 
has been for examining liver working are ALP and 
SGPT. Biliary blockage can be checked through 
enhanced activity of plasma ALP. Although, it does 
not point out the region of blockage [4]. Damage of 
liver can be checked through an enhanced level of 
cytoplasmic enzyme SGPT. For patients of hepatitis C, 
the significance of interferon alpha has been 
considered. In the management of membrane 
proliferate glomerulonephritis, the interferon alpha 
may prove effective. It reduces the incidence of end-
stage renal disorder with the main economic 
suggestion for a person and community as well [5]. 
The objective of this study was to determine to the 
efficiency of alpha-interferon on the levels of serum 
bilirubin, Alkaline phosphate and SGPT in patients of 
Hepatitis C. 
 
MATERIAL AND METHODS: 
This research was completed in the timeframe of 
February to August 2018 at Jinnah Hospital, Lahore. 
Total patients were selected for study were 20 males 
diagnosed with Hepatitis C. The age bracket for these 
patients was between 24 – 51 years of age. The 
selected patients were provided with an injection of a-
interferon three times a week. After execution of 6 
months of chemotherapy, their sera were assessed. 
Before and after chemotherapy with alpha interferon 
for 6 months, the assessment was made for levels of 
serum total, ALP, SGPT and direct and indirect 
bilirubin for all patients. Before and after 
chemotherapy with alpha interferon, the levels of 
SGPT in all the selected patients of hepatitis C were 
measured. Outcomes are illustrated in tables. 
 
By using the kit method of Merck diagnostic [6], 
serum total bilirubin (STB) was assessed. While by 
using the technique of Schellong and Wende, the 
assessment was made for the serum direct bilirubin 
(SDB) level [7]. Through kinetic calorimetric 
technique using the kit designed by Merk diagnostic 
alpha-interferon, the level of serum Alkaline 
Phosphate was examined by optimized UV test SGPT 
was estimated [8]. 
 
RESULTS: 
The number of patients who became negative for HCV 
after six months of management with a-interferon was 
18 (90%). The levels of serum total bilirubin before 
and after management with a-interferon were (0.939 ± 
0.07) mg/dl and (0.924 ± 0.09) mg/dl respectively 
which were normal. The outcomes noticed for serum 
direct and indirect bilirubin were identical. Before 
treatment, there observed elevated levels of serum 
Glutamate Pyruvate Transaminase (SGPT) (337.40 ± 
75.38) U/I and after management with a-interferon, 
these levels became normal (26.8 ± 7.42) U/I before 
and after management with a-interferon, the levels of 
alkaline phosphatase (ALP) were normal in patients of 
our study. Detailed outcomes are shown in the given 
tabular data: 
 
Table – I: Serum Values Before and After Treatment 
 
Serums 
Before Treatment After Treatment 
Mean ±SD Mean ±SD 
Serum Total Bilirubin 
STB md/dl 
0.9359 0.76 0.89 0.89 
Serum Direct Bilirubin 
SDB md/dl 
0.503 0.117 1.28 1.28 
Serum Indirect Bilirubin 
SIB md/dl 
0.436 0.08 0.073 0.073 
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Table – II: SGPT and ALP Values Before and After Treatment 
 
Serums 
Before Treatment After Treatment 
Mean ±SD Mean ±SD 
SGPT (U/L) 337.4 75.38 26.8 7.42 
ALP (U/L) 211.1 7.42 211.55 64.075 
 
 
 
 
 
The average ALP values of patients before 
chemotherapy were (211.10 ± 65.194) U/I and after 
chemotherapy was (211.55 ± 64.075) U/I. 
Comparative to personal values, very small 
dissimilarity was indicated by outcomes in case of 
only a few patients. Before and after chemotherapy, 
the dissimilarity between the levels of ALP was not 
valuable (P > 0.05). The STB range before treatment 
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were (0.73 ± 1.38) mg/dl and after treatment were 
(0.78 – 1.12) mg/dl. Dissimilarity in the personal 
levels according to results were negligible. The 
average values of STB before treatment with alpha-
interferon were (0.939 ± 0.076) mg/dl and after 
treatment were (0.924 ± 0.089) mg/dl. No valuable 
dissimilarity was indicated through statistical 
assessment by T-Test (P > 0.05). 
 
Less dissimilarity was indicated by the personal values 
of SDB. Before management, this dissimilarity 
changes from 0.33 to 0.76 mg/dl in patients. While 
after chemotherapy for six months, this change was 
from 0.35 – 0.77 mg/dl. Before management, the 
average SDB values were (0.503 ± 1.17) mg/dl; 
whereas, after management, these values were (0.494 
± 1.28) mg/dl. No valuable dissimilarity was shown by 
the comparison of SDB values by T-Test (P > 0.05). 
 
Before and after management with alpha-interferon, 
the average values of SIB were (0.436 ± 0.08) and 
(0.422 ± 0.073) mg/dl respectively. At personal levels, 
very small dissimilarity was observed. Before and 
after chemotherapy, no valuable dissimilarity between 
SIB values was indicated by T-Test (P > 0.05). 
 
The frequency of liver cells chemotherapy damage is 
given by the range of increased levels of SGPT 
(262/422 U/I) in chronic hepatitis C patients before 
treatment. But, there noticeda decrease in the level of 
SGPT in these patients after treatment with alpha-
interferon. At the end of six months chemotherapy, 
these levels fell to normal (16 – 47 U/I). Before 
management, the average values of SGPT were 
(337.40 ± 75.38) and after treatment, these levels were 
(26.8 ± 7.42) U/I. The dissimilarity in the levels of 
SGPT levels by T-Test was very valuable (P < 0.001). 
 
DISCUSSION: 
Excretory working of the liver remains within normal 
range in the beginning stage of chronic hepatitis. It is 
due to the fact that necrosis or fibrosis or liver damage 
are not dispersed [2]. Before and after management 
with alpha-interferon, the levels of serum total 
bilirubin remained normal in our study. The levels of 
serum direct bilirubin and serum indirect bilirubin also 
remained normal. Similarly, the levels of ALP in 
chronic hepatitis C patients were also normal. Before 
the establishment of cirrhosis of liver cancer in chronic 
hepatitis C, the pressure was normal in the biliary 
canaliculi. ALP is found in hepatocytes, attached to 
hepatocyte membrane. When there is a blockage in the 
biliary passage, the ALP in the liver disorder is 
elevated just then [3]. No blockage was observed in 
our patients and the patients in our study were in the 
beginning stage of chronic hepatitis. So, the level of 
ALP remained within normal range. SGPT is a 
significant measure of liver cells damage [10]. The 
level of SGPT in healthy people remains normal (9 – 
40) U/I. Whereas, its occurrence is elevated due to 
viral infection in chronic hepatitis C. Higher dose of 
IFN (SMU, thrice weekly) were provided to patients 
in previous studies. Moreover, a supportive reaction 
was imagined on the management of normal ALT 
values [11]. The SR (Sustained Response) rates ranged 
from 82% and biochemical end of therapy response 
(ETR) rates ranged from (30 – 50) percent when IFN 
was used at a dose level of 3 million units, 3 times 
weekly for a period of 6 months. The virologic SR 
rates varied from 27% to 35% [12]. It was explained 
by Hoofnagle et al [3] that when interferon alpha was 
provided to patients with non-A, Non-B hepatitis was 
able to normalize the levels of an enzyme of the liver 
in a considerable number of patients.  
 
CONCLUSION: 
It is concluded from the results that working of the 
liver is enhanced by alpha-interferon. It was also 
indicated that under the environment of Pakistan, 
chronic Hepatitis C is effectively managed alpha-
interferon. In order to prevent any incidence of 
relapses, doses of alpha-interferon should be taken 
continuously and chemotherapy should not be 
stopped. 
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